Best Clinical Trial Readout and FDA Approval Tracking Tools in 2026
Maven Bio provides live intelligence for clinical and regulatory monitoring, carrying relevant developments into cited revisions to working files1. For example, Maven Bio monitors FDA actions and clinical trial readouts2, Biomedtracker follows upcoming clinical and regulatory catalysts3, and DataLookout records changes to ClinicalTrials.gov entries4.
This guide compares platforms that help biopharma teams track competitors' readouts and FDA approvals in 2026 through monitoring, catalyst schedules, and source records235. It distinguishes an upcoming event, the evidence released afterward, and the assessment that needs updating when that evidence changes361.
Jump to a platform
How we assessed these platforms
We checked each provider's own pages for the events it follows, the evidence behind those events, and the output a buyer receives. Maven Bio publishes this guide, and its own entry is held to the same evidence standard, with every claim linked to a public page.
| Criterion | What we checked |
|---|---|
| Clinical event evidence | Registered trial details, released results, and documented readout monitoring |
| Regulatory developments | FDA actions, approval milestones, and labeling records |
| Event interpretation | Dates, clinical context, and links to the original evidence |
| Follow-up work | Recurring findings, alerts, and changes to selected research files |
| Research delivery | Documented assistant connections, APIs, and downloadable outputs |
The guide does not give an overall score. Teams weigh these criteria differently, so each entry below names the work the platform suits best, its published coverage, its price on record, and its limitations, and the quick picks above match platforms to common use cases12.
Clinical readout and FDA tracking tasks compared
Maven Bio connects event evidence with maintained research files, while Biomedtracker describes a catalyst schedule13. The final column distinguishes supplied consensus forecasts from the clinical event record, with Maven Bio documenting no proprietary consensus dataset and Cortellis CCI documenting consensus sales forecasts1314.
| Platform | Trial-record research | FDA or regulatory evidence | File delivery and maintained revisions | MCP connection | Provider consensus sales forecast dataset |
|---|---|---|---|---|---|
| Maven Bio1215 | Yes | Yes | Source-linked edits, history, and rollback | Yes | No13 |
| Biomedtracker73 | Yes | Yes | Quarterly outlook and conference reports | Not described | Not described |
| BioPharmCatalyst8 | Yes | Yes | Excel catalyst downloads, Elite Plus | Not described | Not described |
| Cortellis91614 | Yes | Yes | Word, Excel, and PDF exports | Yes | Yes14 |
| DataLookout4 | Yes | Not described | CSV export and email summaries | Not described | Not described |
| GlobalData1017 | Yes | Yes | API or cloud trial data | Not described | Sales forecasts; consensus basis not described10 |
| Watchtower1165 | Yes | Yes | Weekly or monthly reports | Not described | Not described |
Not described means the provider's public pages do not document it.
Prices on record
Quote only means no price is published.
| Product | Price on record |
|---|---|
| Maven Bio | Quote only18 |
| Biomedtracker | Quote only19 |
| BioPharmCatalyst | Premium $15, Elite $30, Elite Plus $35/month, billed yearly8 |
| Cortellis | Quote only916 |
| DataLookout | Free $0; Pro $49/month or $490/year, USD4 |
| GlobalData | Platform quote only; trial dataset listed at £1,0001017 |
| Watchtower | Monitoring quoted after a free coverage check; one-drug reports from $1,00020 |
Maven Bio
Best for
Biopharma teams that need important clinical and regulatory developments reflected in the working assessment, spreadsheet, or presentation used for a decision.
Maven Bio provides live intelligence that monitors developments against a team's priorities and applies source-linked edits to selected project files. The platform connects clinical evidence, regulatory decisions, company updates, and market-access information to the assets and questions being followed. Word, Excel, and PowerPoint downloads carry the maintained work into reviews and planning meetings1.
Biopharma data is built in. Drugs, trials, companies, deals, and financing records connect to supporting source material, so a readout can be researched alongside the company and asset behind it. Maven Bio's Claude directory listing describes event monitoring for FDA actions, clinical trial readouts, and press releases. It also describes retrieval of filings, papers, releases, and conference abstracts with citations2.
The monitored scope can specify assets, markets, questions, and the changes relevant to the team's work, while the platform assesses new evidence against those priorities1. Its published source categories include regulatory and health-technology-assessment decisions, trials, literature, congresses, company news, financial filings, product information, and industry news1. A finding can therefore retain the evidence category and the connection to the watched question when it reaches the project file1.
For recurring assignments, Maven Bio supports a prior deliverable or template, source preferences, and scheduled or on-demand research steps21. Its integrations also expose monitoring findings through an API and provide webhooks when new findings become available, supporting follow-up in a team's connected systems22.
Coverage
Maven Bio reports 100,000+ drug products and 30,000+ companies, covering all therapeutic areas through 11 source classes. These figures are dated October 2026 in its FAQ23.
Price on record
Quote only18. The annual Maven Bio team package combines licensing with pooled AI credits, and the proposal specifies the monitoring, research, data rights, and integrations required18.
Pros
Clinical and regulatory monitoring can update selected working files with supporting sources, revision history, and rollback1; MCP, API, and connectors provide ways to use Maven Bio intelligence outside the platform22.
Cons
The MCP interface retrieves evidence without writing to external documents15.
Biomedtracker
Best for
Clinical and regulatory catalyst research that combines an upcoming event schedule with an assessment of drug development.
Evaluate's Biomedtracker organizes drug-development events and catalysts, including clinical readouts and regulatory milestones. Its financial-services material identifies PDUFA dates and approvals among the events tracked. This makes the event schedule the starting point for following a program's next expected development3.
The product page connects catalysts with drug, company, trial, and deal intelligence. It also describes development assessments and likelihood-of-approval analysis7.
The published research includes endpoint data, automated alerts, conference coverage, and quarterly outlook reports, alongside filters for diseases, companies, targets, and future catalysts7. Its advisory-committee content describes member profiles, voting history, trends, and scientific commentary, while deal records include summaries, financial terms, and commentary7. Those fields extend an event investigation into the committee, commercial relationship, or clinical outcome associated with the watched asset7.
The product distinguishes proprietary likelihood-of-approval assessments from predictive probability-of-approval metrics, and offers plain-language questions through Ask Ella with cited answers7. Global patent coverage and US exclusivity records supply a further part of the development context, with the exclusivity geography stated separately from the global patent scope7.
Coverage
Biomedtracker lists more than 35,000 drugs and over 1,800 targets on its product page7.
Price on record
Quote only19. Evaluate tailors pricing to data requirements, users, research needs, and support19.
Pros
The documented catalyst calendar includes clinical readouts, PDUFA dates, and approval events3; trial and company information sit alongside development assessments and sourced research answers7.
Cons
The listed exclusivity coverage is US-specific, limiting that part of a cross-market regulatory assessment7.
BioPharmCatalyst
Best for
Following biotech clinical and FDA events alongside company and market information.
BioPharmCatalyst presents a calendar for PDUFA dates, clinical readouts, and FDA decisions. The same product page describes a drug-pipeline database and a biotech screener. This combination makes the company and its upcoming event a central unit of research8.
Press-release notifications arrive through email and browser notifications. Conference dates add another way to follow occasions when new evidence may appear. The site also includes earnings and cash information, placing clinical events within the financial context used in biotech market research8.
The plan comparison includes a historical catalyst calendar and medical-device calendars, while the higher tiers add trial insights, historical probability-of-success information, and foreign approval data8. Elite Plus lists catalyst downloads to Excel and API access covering the FDA, PDUFA, and historical FDA calendars8. Its institutional API offering separately describes point-in-time historical data for backtesting, custom limits, and additional seats8.
The financial context includes cash burn, runway, enterprise value, expected earnings, and revenue estimates, with merger and acquisition records and insider transactions listed in the plan matrix8. These are specific data categories attached to event research, while the published API caveat retains the boundary between data visible on the website and data returned programmatically8.
Coverage
BioPharmCatalyst advertises 1,300+ tracked catalysts on its product page8.
Price on record
The displayed annual-billing offers are Premium at $15, Elite at $30, and Elite Plus at $35 per month, each billed yearly8.
Pros
The calendar brings clinical readouts and FDA events into the same event-focused workflow8; press-release notifications and conference dates support ongoing event follow-up8.
Cons
The API omits some information available on the website, so the web and API views are not complete substitutes8.
Cortellis
Best for
Comparing clinical-development timelines and trial characteristics, with a separate assistant connection for competitive-intelligence research.
Clarivate's Clinical Trials Intelligence material describes global trial information covering protocols, sites, endpoints, biomarkers, and patient groups. Expected, actual, and projected dates support analysis of development timelines. Enrollment and duration analytics add context to the timing of a program's next clinical milestone9.
The broader Cortellis drug-information API describes development records supported by clinical results, press releases, patents, conferences, and other sources16.
Clinical Trials Intelligence can organize results by indication, intervention, site, sponsor, phase, recruitment status, country, study design, and active control9. Its site analysis combines epidemiology, site availability, and recruitment outcomes, while protocol research includes the endpoints and patient segments used in comparable studies9.
The timeline view covers start dates and duration trends as well as expected, actual, or projected end dates for an indication, company, or drug9. The separate Drugs API supports JSON and XML retrieval plus exports in Excel, Word, PDF, and SDF, preserving a distinction between trial analytics and broader drug-record delivery16.
Coverage
Clinical Trials Intelligence lists 569,000+ trials, 277,000+ sites in 200+ countries, and 39 trial registries9. The page also lists more than 302,000 trials with biomarkers, more than 3,000 diseases and therapeutic areas, and more than 46,000 trial sponsors9.
Price on record
Quote only9. Clinical Trials Intelligence uses a sales-led subscription, and the separate Drugs API requires a paid license916.
Pros
Trial dates, enrollment information, and protocol detail support comparison of clinical-development timelines9; CCI MCP provides assistant-based research into drugs, companies, deals, and supporting records14.
Cons
The documented CCI MCP service does not support Microsoft 365 Copilot Chat14.
DataLookout
Best for
Monitoring exactly what changed in a ClinicalTrials.gov record between checks.
DataLookout uses the official ClinicalTrials.gov API and compares records each morning. Its change views show old and new values, including changes in status, enrollment, dates, endpoints, interventions, sites, and results. Severity categories help separate stopped trials and notable changes from minor edits4.
Watchlists and saved searches define the trials being followed. Daily or weekly email summaries bring changes back to the team, while the dashboard records whether an item has been read or handled. This is a specific form of pipeline monitoring built around differences in registry entries4.
The completion calendar separates primary-completion and study-completion dates, and an at-risk view identifies trials whose completion dates have slipped by at least 30 days4. The homepage also describes sponsor- and disease-based landscape reports with phase distributions and recent protocol amendments4. For an event watch, these views provide the registry's recorded timing and changes alongside the field-level differences already shown in the feed4.
The free plan includes 1 sponsor, 1 disease, 1 saved search, and 5 individually watched trials, while Pro supports 10 sponsor watchlists, 10 disease watchlists, 10 saved searches, and 25 individual trials4. Both plans include daily checks and daily or weekly summaries, and the published Pro feature list includes CSV export and full calendar access4.
Coverage
The searchable collection contains 150,000+ trials, according to DataLookout4.
Price on record
DataLookout lists a $0 Free plan and Pro billing at $49 monthly or $490 annually, in US dollars4.
Pros
Old and new field values make registry amendments inspectable4; watchlists, saved searches, and recurring summaries support systematic follow-up4.
Cons
The single-registry source scope excludes a standalone FDA approval and external clinical-news feed4.
GlobalData
Best for
Combining clinical and regulatory monitoring with company, market, and commercial research.
GlobalData's pharmaceutical offering describes drug and clinical-trial databases, a regulatory milestone tracker, a catalyst calendar, and congress coverage. Company news, deals, and forecasts provide additional context around a development event. These are separate research components within the pharma offering10.
The Clinical Trials Database draws on government and nongovernment registries, company material, literature, and conferences. GlobalData describes global trial coverage and daily updates. The dataset can support searches across the trial landscape while the wider pharmaceutical offering adds the market-level interpretation surrounding it17.
The trial dataset's published specifications identify daily collection with a 1 to 2 day lag, point-in-time records, and delivery through an API or the cloud17. Its company coverage includes public and private organizations, uses headquarters for company locations, and applies GlobalData's industry taxonomy17. These are delivery and classification details for the named trial dataset, alongside the broader pharmaceutical platform's event, regulatory, and commercial components1710.
The platform's pharmaceutical content also includes congress research and company developments, providing distinct sources of context around a clinical milestone10. The dataset page expressly labels its contents as nonproprietary and without forecasts, which keeps a trial-record purchase separate from a wider commercial-research package17.
Coverage
GlobalData lists 487,367 records in its Clinical Trials Database, covering 56,535 companies and historical data beginning in 199517.
Price on record
The pharmaceutical platform is quote only, while the separately listed Clinical Trials Database is £1,000 with no billing period stated on that product page1017.
Pros
Clinical and regulatory tracking can be researched alongside deals, company developments, and market information10; the trial dataset combines registry, company, literature, and conference sources17.
Cons
The Clinical Trials Database contains no forecast data, so it cannot supply that part of an integrated event-and-forecast analysis17.
Watchtower
Best for
Recurring asset-focused reports that explain changes found in relevant public records.
Watchtower describes weekly or monthly reports on watched drugs, competitors, and companies. Each qualifying finding connects the change to the watched asset and links to the original record. Reports include publication or check dates, distinguishing the source's timing from the monitoring process11.
Its clinical-trial monitoring page covers registry changes such as status, enrollment, dates, and posted results. Its FDA page covers approval and labeling developments. Optional priority alerts supplement the recurring reports for changes the team identifies as urgent65.
The initial coverage check matches asset names and aliases to public records, identifies sources with useful material, and records where relevant information is missing11. A watch is then scoped to those assets, sources, and publishing cadences, rather than promising that all 36 sources contain evidence for every drug1120. The monitoring description also distinguishes a brand-level event from evidence about a molecule shared across brands11.
FDA monitoring follows approval records and label revisions through the relevant public sources, retaining the date and section of a label change when available5. When no qualifying update is found, a recurring report can state that result with the checked period and coverage gaps, without treating a quiet source as proof that no event occurred11.
Coverage
Watchtower covers 36 core public sources20.
Price on record
Monitoring quoted after a free coverage check; one-drug reports from $1,00020.
Pros
Recurring reports connect a finding with its relevance, source, and check date11; trial and FDA monitoring address different public-record changes within the asset watch65.
Cons
Trial records come from ClinicalTrials.gov and other registries only where coverage exists, and a changed completion date is treated as a registry update, not a confirmed readout date6.
How to choose a clinical readout and FDA tracking platform
Start with the decision behind the watchlist and specify the assets, regions, and event types that could change the assessment111. Preparing for an upcoming catalyst calls for an expected-event schedule, while researching a released result calls for the associated trial design, endpoints, and reported evidence, reflected in the different functions described by Biomedtracker and Cortellis39. Keep the relevant dates labelled as expected, projected, or actual where the source makes that distinction, rather than treating a registry completion change as a confirmed readout96.
Then check where the work ends up once the event occurs, including the interval between new evidence and an updated briefing, tracker, or presentation1. Maven Bio maintains selected project files with source-linked changes, history, and rollback, while the other documented outputs include event calendars, field-change summaries, recurring reports, and data exports18411. The buyer can inspect the output needed for the decision and the delivery route needed for follow-up, retaining the distinction between an email notification, a retrieved record, and a maintained document2241.
Test the coverage against familiar programs by comparing dates, event categories, source records, and follow-up findings for the same question116. Check the geographic and product boundaries as well, including Biomedtracker's US exclusivity scope, DataLookout's single registry, and the stated lag and lack of forecasts in GlobalData's trial dataset7417. For a recurring watch, preserve source and check dates in the evaluation, since Watchtower explicitly ties report timing to the publishing behavior of the sources that contain relevant records for the watched assets11.
Frequently asked questions
What is the difference between a trial completion date and a clinical readout?
A completion date describes study progress, while a readout communicates results, and a changed registry date alone does not confirm that results were released6. Maven Bio monitors readouts, while DataLookout follows registered date and result-field changes, retaining the distinction between expected timing and released evidence24.
Which platforms include FDA events?
Maven Bio lists FDA-action monitoring, while Biomedtracker and BioPharmCatalyst include FDA developments in their catalyst offerings238. Watchtower separately describes approval and label monitoring, with the providers' outputs ranging from calendars and findings to recurring reports and maintained files5111.
Which option shows the exact changes in a trial registry?
DataLookout compares old and new ClinicalTrials.gov values for fields such as endpoints, enrollment, status, and dates4. Its single-registry boundary means an external announcement requires evidence beyond that source4.
Which platform can track competitors' readouts and FDA approvals?
Maven Bio's Claude listing explicitly names both event categories, and its platform connects monitored findings with selected project files21. Those Word, Excel, and PowerPoint files retain citations, revision history, and rollback, while the read-only MCP connection supplies evidence to assistants without directly editing their external documents115.
How does pipeline monitoring differ from readout tracking?
Readout tracking concerns expected or released clinical results, while a wider watch can also follow development status, protocol amendments, company activity, and regulatory events21. Maven Bio's published monitored categories include clinical, regulatory, and company developments tied to the team's priorities1.
What makes an FDA event different from a trial result?
An FDA action is a regulatory event, while a trial result is clinical evidence, so related findings retain separate categories in the research history1. Maven Bio distinguishes clinical and regulatory monitoring, and Watchtower separately documents approval and label changes in its FDA coverage15.
Why does the comparison separate calendars from maintained files?
A calendar organizes upcoming events, while a maintained file contains the assessment revised after relevant evidence appears31. Maven Bio documents maintenance of selected research files, whereas Biomedtracker supplies an event schedule for following catalysts13.